Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
CXCL8 3576 ALPRAZOLAM CHEMBL661 NCI 12218154
CXCL8 3576 TERFENADINE CHEMBL17157 NCI 8919641
CXCL8 3576 IONOMYCIN CHEMBL501617 NCI 7510691
CXCL8 3576 METHYLENE BLUE CHEMBL191083 NCI 12500513
CXCL8 3576 PENTOXIFYLLINE CHEMBL628 NCI 12576442
CXCL8 3576 CHEMBL262489 CHEMBL262489 DrugBank
CXCL8 3576 RIVANICLINE CHEMBL132966 antagonist DrugBank 16715250
CXCL8 3576 ACETAMINOPHEN CHEMBL112 NCI 15878691
CXCL8 3576 ASPIRIN CHEMBL25 NCI 12576442
CXCL8 3576 TROGLITAZONE CHEMBL408 NCI 12364456
CXCL8 3576 BEVACIZUMAB CHEMBL1201583 PharmGKB
CXCL8 3576 TOCOPHEROL ACETATE CHEMBL1047 NCI 15150308
CXCL8 3576 METHIMAZOLE CHEMBL1515 NCI 11453524
CXCL8 3576 MIDAZOLAM CHEMBL655 NCI 9620522
CXCL8 3576 PHORBOL MYRISTATE ACETATE CHEMBL279115 NCI 7510691
CXCL8 3576 HuMax-IL8 CHEMBL2109617 inhibitor ChemblInteractions
CXCL8 3576 CETUXIMAB CHEMBL1201577 NCI 15908664, 10614716, 10037173
CXCL8 3576 LANSOPRAZOLE CHEMBL480 NCI 17122965
CXCL8 3576 OMEPRAZOLE CHEMBL1503 NCI 17122965
CXCL8 3576 PAMIDRONIC ACID CHEMBL834 NCI 12006522
CXCL8 3576 TALC CHEMBL1200568 NCI 17000556
CXCL8 3576 ABX-IL8 CHEMBL2109616 inhibitor ChemblInteractions
CXCL8 3576 CYCLOPHOSPHAMIDE CHEMBL88 PharmGKB
CXCL8 3576 ALUMINUM HYDROXIDE CHEMBL1200706 NCI 10466876
CXCL8 3576 CLARITHROMYCIN CHEMBL1741 NCI 12003967
CXCL8 3576 LEFLUNOMIDE CHEMBL960 NCI 10902750
CXCL8 3576 CEFTRIAXONE CHEMBL161 NCI 8011012
CXCL8 3576 DANAZOL CHEMBL1479 NCI 16161451
CXCL8 3576 HYDROQUINONE CHEMBL537 NCI 17118622
CXCL8 3576 MEDROXYPROGESTERONE ACETATE CHEMBL717 NCI 15914533
CXCL8 3576 PACLITAXEL CHEMBL428647 NCI 9271387
CXCL8 3576 TRETINOIN CHEMBL38 NCI 8900181
CXCL8 3576 RUTIN CHEMBL226335 NCI 9292787
CXCL8 3576 FENRETINIDE CHEMBL7301 NCI 16979119
CXCL8 3576 FENTANYL CHEMBL596 NCI 9527747
CXCL8 3576 FOSCARNET CHEMBL666 NCI 10630964
CXCL8 3576 CHEMBL1213492 CHEMBL1213492 NCI 12010777
CXCL8 3576 NAPROXEN CHEMBL154 NCI 11852880
CXCL8 3576 VERAPAMIL CHEMBL6966 NCI 2686646
CXCL8 3576 CIDOFOVIR CHEMBL152 NCI 10630964
CXCL8 3576 DIPYRIDAMOLE CHEMBL932 NCI 10660968

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
CXCL8 rs4073 AA ranibizumab efficacy yes Genotype AA is associated with decreased response to ranibizumab in people with Macular Degeneration as compared to genotypes AT + TT. 26653034 1447676333
CXCL8 rs4073 AA + AT bevacizumab efficacy yes Genotypes AA + AT are associated with decreased response to bevacizumab and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT. 19010874 827822867
CXCL8 rs4073 AA bevacizumab efficacy yes The A allele was more frequent in non-responders than in responders or partial responders. Responder status was determined by optical coherence tomography; please refer to the paper directly for definitions of responder, partial responder, and non-responder. Genotype AA is associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotypes AT + TT. 23584701 1184166127
CXCL8 rs4073 T cetuximab efficacy no Meta-analysis with 3 studies. The authors did not provide the exact number of patients but stated that "the median number of patients per analysis was 110 (range 50 - 740)". Most definitions of response were variations of the RECIST criteria. Allele T is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to allele A. 27897268 1449165388